Pyranosyl cytosines: pharmaceutical formulations and methods
US6933288B2 · kind B2 · utility
20Cited by
0References
41Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 4, 2002 |
| Grant date | Aug 23, 2005 |
| Priority date | — |
| Expiry date | Aug 23, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is directed to novel pyranosyl cytosine compounds depicted graphically as structure I. This invention is further directed to a unique methodology for their preparation using solid-phase methodology. These hexopyranosyl cytosine derived natural product analogs share their parent compounds broad-spectrum antimicrobial and anti-fungal profile and represent a vast, novel compound class of 50S rRNA directed inhibitors of protein translation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.